This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

60/100

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022). Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(22)00168-5

Vancouver

Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. The Lancet. Neurology. 2022. doi:10.1016/s1474-4422(22)00168-5. PMID: 35643092.

BibTeX

@article{ossenkoppele2022-35643092,
  author  = {Ossenkoppele, R. and van der Kant, R. and Hansson, O.},
  title   = {{Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials}},
  journal = {The Lancet. Neurology},
  year    = {2022},
  doi     = {10.1016/s1474-4422(22)00168-5},
  pmid    = {35643092},
  url     = {https://doi.org/10.1016/s1474-4422(22)00168-5}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy.
WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding.
Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement.
Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities.
Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.

Why it matters

This paper states that neuroimaging and biofluid tau markers hold potential for optimising clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. Major challenges to overcome include the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding.

New to this subject? Start with our plain-English guide: Getting a diagnosis →

Study details

Study designclinical trial
Evidence strengthLow

How this study scored 60/100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record	3 / 4	The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design	0 / 12	Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2022 — within 6 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	6 / 7	Cited 546 times (OpenAlex, 2026-10-10)
Citations per year	5 / 5	91.0 citations a year over 6 year(s) since 2022
Impact for its field and year	6 / 6	Cited 55.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	4 / 6	Cited by 30 other studies in this library
Still being cited	4 / 4	Cited 432 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career)
Institution's track record	1 / 3	Lund University: institution h-index 1,119 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 35643092)
Free to read	0 / 2	Behind a paywall — scores zero
Total	60 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.

Later studies that cite this one

30 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →